Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02548455 · ClinicalTrials.gov registry record · NA

Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study

A NA study of Heart Failure, sponsored by Abbott Medical Devices.

Completed
Registry status
NA
Development phase
499
Enrollment target
20
Study locations

NCT02548455 is a NA study of Heart Failure that has completed, run by Abbott Medical Devices. The registered enrollment target is 499 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02548455, a NA study of Heart Failure, has completed, sponsored by Abbott Medical Devices.

COMPLETED
Registry status
NA
Development phase
499 participants
Enrollment target
20
Study locations

Study Summary

The primary intent of this study is to assess the safety of the model 1457Q Quartet LV lead at 3 months in a patient population indicated for cardiac resynchronization therapy.

Conditions Studied

Interventions

  • DEVICE Quartet 1457Q LV Lead

Study Locations (20)

California

  • Scripps Health - La Jolla
  • Premier Cardiology, Inc. - Newport Beach
  • Stanford University Hospital - Stanford

Florida

  • Munroe Regional Medical Center - Ocala
  • Tallahassee Research Institute - Tallahassee

Georgia

  • Emory University Hospital - Atlanta
  • North Georgia Heart Foundation - Gainesville

Kentucky

  • Central Baptist Hospital - Lexington
  • One Health Cardiology - Owensboro

Massachusetts

  • Massachusetts General Hospital - Boston
  • Brigham and Women's Hospital - Boston

Alabama

  • Heart Center Research - Huntsville

Arizona

  • Arizona Arrhythmia Research Center - Phoenix

Arkansas

  • Cardiology Associates of Northeast Arkansas - Jonesboro

Trial Details

FieldValue
Enrollment Target 499 participants
Start Date 2015-10-27
Est. Completion 2017-03-21
Phase NA

Sponsor

Abbott Medical Devices

261 total trials

What the Registry Record Tells You About NCT02548455

The ClinicalTrials.gov registry entry for NCT02548455 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 499 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (76% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Quartet 1457Q LV Lead is the first listed.

NCT02548455 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT02548455 about?

NCT02548455 is a clinical study titled "Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study". The primary intent of this study is to assess the safety of the model 1457Q Quartet LV lead at 3 months in a patient population indicated for cardiac resynchronization therapy.

What is the current status of trial NCT02548455?

This trial is currently completed. It is a NA study. The enrollment target is 499 participants. The study started on 2015-10-27. Estimated completion is 2017-03-21.

What conditions does trial NCT02548455 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT02548455?

The interventions under investigation include: Quartet 1457Q LV Lead (DEVICE).

Who is sponsoring clinical trial NCT02548455?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02548455 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.